<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153163</url>
  </required_header>
  <id_info>
    <org_study_id>BP29920</org_study_id>
    <nct_id>NCT03153163</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer</brief_title>
  <official_title>A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase I study of single-agent trastuzumab emtansine administered by&#xD;
      intravenous (IV) infusion. The study will characterize the pharmacokinetics of trastuzumab&#xD;
      emtansine and its relevant analytes and the safety of trastuzumab emtansine in Chinese&#xD;
      participants with human epidermal growth factor receptor 2 (HER2)-positive locally&#xD;
      advanced/metastatic breast cancer (LA/MBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">September 27, 2018</completion_date>
  <primary_completion_date type="Actual">September 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve [AUC] of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1</measure>
    <time_frame>Pre-dose, 30 minutes (min), 24, 48, 72/96 hours (hr) post-dose, Day 8, 11, 15, 18 post-dose; Pre-dose, 30 min post-dose Cycle 2 Day 1, Cycle 3 Day 1; Pre-dose Cycle 4 Day 1</time_frame>
    <description>AUC will be evaluated and reported for trastuzumab emtansine and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax) Immediately After Dosing of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1</measure>
    <time_frame>Pre-dose, 30 minutes (min), 24, 48, 72/96 hours (hr) post-dose, Day 8, 11, 15, 18 post-dose; Pre-dose, 30 min post-dose Cycle 2 Day 1, Cycle 3 Day 1; Pre-dose Cycle 4 Day 1</time_frame>
    <description>Maximum serum concentration (Cmax) immediately after dosing will be evaluated and reported for trastuzumab emtansine and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum (Trough) Concentration (Cmin) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1</measure>
    <time_frame>Pre-dose, 30 minutes (min), 24, 48, 72/96 hours (hr) post-dose, Day 8, 11, 15, 18 post-dose; Pre-dose, 30 min post-dose Cycle 2 Day 1, Cycle 3 Day 1; Pre-dose Cycle 4 Day 1</time_frame>
    <description>Minimum (Trough) Concentration (Cmin) will be evaluated and reported for trastuzumab emtansine and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1</measure>
    <time_frame>Pre-dose, 30 minutes (min), 24, 48, 72/96 hours (hr) post-dose, Day 8, 11, 15, 18 post-dose; Pre-dose, 30 min post-dose Cycle 2 Day 1, Cycle 3 Day 1; Pre-dose Cycle 4 Day 1</time_frame>
    <description>Clearance (CL) will be evaluated and reported for trastuzumab emtansine and its metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution at Steady-State (Vss) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1</measure>
    <time_frame>Pre-dose, 30 minutes (min), 24, 48, 72/96 hours (hr) post-dose, Day 8, 11, 15, 18 post-dose; Pre-dose, 30 min post-dose Cycle 2 Day 1, Cycle 3 Day 1; Pre-dose Cycle 4 Day 1</time_frame>
    <description>Volume of distribution at steady-state (Vss) will be evaluated and reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life (t1/2) of Trastuzumab Emtansine, Total Trastuzumab, N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine (DM1), Non-reducible Thioether Linkage (MCC)-DM1 and Lys-MCC-DM1</measure>
    <time_frame>Pre-dose, 30 minutes (min), 24, 48, 72/96 hours (hr) post-dose, Day 8, 11, 15, 18 post-dose; Pre-dose, 30 min post-dose Cycle 2 Day 1, Cycle 3 Day 1; Pre-dose Cycle 4 Day 1</time_frame>
    <description>Half-life (t1/2) will be evaluated and reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for AEs, Version 4.03 (NCI CTCAE V4.03)</measure>
    <time_frame>Up to (28-42 days) after the last dose of study drug (57 days)</time_frame>
    <description>An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Trastuzumab Emtansine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab Emtansine</intervention_name>
    <description>Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.</description>
    <arm_group_label>Trastuzumab Emtansine</arm_group_label>
    <other_name>RO5304020</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prospective centrally-assessed HER2-positive disease (i.e., immunohistochemistry [IHC]&#xD;
             3 + and/or gene amplified [HER2 to CEP 17 ratio ≥ 2] by in situ hybridization [ISH])&#xD;
             through use of archival paraffin-embedded tumor tissue. Both IHC and ISH assays will&#xD;
             be performed; however, only one positive result from either method is required for&#xD;
             eligibility&#xD;
&#xD;
          -  Tumor tissue block or eight unstained freshly cut slides must be available for central&#xD;
             laboratory HER2 testing. Archival tumor samples obtained from primary and/or&#xD;
             metastatic sites are acceptable&#xD;
&#xD;
          -  For participants with bilateral BC, HER2-positive status must be demonstrated in both&#xD;
             locations or in a metastatic site&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer (BC): incurable,&#xD;
             unresectable, LABC previously treated with multimodality therapy or metastatic breast&#xD;
             cancer (MBC)&#xD;
&#xD;
          -  Prior treatment for BC in the adjuvant, unresectable, locally advanced, or metastatic&#xD;
             setting must include taxane, alone or in combination with another agent, and&#xD;
             trastuzumab, alone or in combination with another agent in the adjuvant, unresectable,&#xD;
             locally advanced, or metastatic setting&#xD;
&#xD;
          -  Documented progression of incurable, unresectable LABC or MBC: Progression must occur&#xD;
             during or after most recent treatment for LABC or MBC or within 6 months after&#xD;
             completing adjuvant therapy&#xD;
&#xD;
          -  Baseline disease that must be evaluable per Response Evaluation Criteria for Solid&#xD;
             Tumors Version 1.1 (RECIST v1.1). Participants with CNS-only disease are excluded&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram (ECHO) or&#xD;
             multiple-gated acquisition (MUGA)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with trastuzumab emtansine, lapatinib, or capecitabine&#xD;
&#xD;
          -  Last dose of prior chemotherapy or trastuzumab within 21 days before the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  Hormonal therapy within 7 days before the first dose of study treatment&#xD;
&#xD;
          -  Treatment with any other anti-cancer therapy/investigational drug (not defined above)&#xD;
             within 21 days prior to randomization, except hormone therapy, which can be given up&#xD;
             to 7 days prior to randomization; recovery of treatment-related toxicity consistent&#xD;
             with other eligibility criteria before the first dose of treatment&#xD;
&#xD;
          -  Radiation therapy within 2 weeks before the first dose of study treatment, and with&#xD;
             any related acute toxicity (Grade ≥1)&#xD;
&#xD;
          -  Brain metastases that are untreated, symptomatic, progressive, or require therapy,&#xD;
             such as radiation or surgery, within 28 days before the first dose of study treatment&#xD;
&#xD;
          -  History of other malignancy within the previous 5 years, except for appropriately&#xD;
             treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine&#xD;
             cancer, synchronous or previously diagnosed HER2-positive BC, or cancers with a&#xD;
             similar curative outcome as those mentioned above&#xD;
&#xD;
          -  Peripheral neuropathy Grade ≥3 per National Cancer Institute Common Toxicity Criteria&#xD;
             for Adverse Events (NCI CTCAE) v4.03&#xD;
&#xD;
          -  History of exposure to the following cumulative doses of anthracyclines as specified&#xD;
             below:&#xD;
&#xD;
               -  Doxorubicin &gt; 500 mg/m^2&#xD;
&#xD;
               -  Epirubucin &gt; 720 mg/m^2&#xD;
&#xD;
               -  Mitoxantrone &gt; 120 mg/m^2 If another anthracycline or more than one anthracycline&#xD;
                  has been used, then the cumulative dose must not exceed the equivalent of 500&#xD;
                  mg/m^2 doxorubicin.&#xD;
&#xD;
          -  Cardiopulmonary dysfunction as defined by:&#xD;
&#xD;
               -  Uncontrolled hypertension (persistent systolic blood pressure &gt;150 millimeter of&#xD;
                  mercury (mmHg) and/or diastolic blood pressure &gt;100 mmHg despite&#xD;
                  anti-hypertensive therapy)&#xD;
&#xD;
               -  Unstable angina or serious cardiac arrhythmia not controlled by medication&#xD;
&#xD;
               -  Baseline LVEF &lt;50% by either ECHO or MUGA scan&#xD;
&#xD;
               -  History of symptomatic congestive heart failure (Grade ≥3 per NCI CTCAE v4.03 or&#xD;
                  Class ≥II per New York Heart Association criteria)&#xD;
&#xD;
               -  History of LVEF &lt;40% or symptomatic CHF during prior trastuzumab treatment&#xD;
&#xD;
               -  Myocardial infarction within 6 months before the first dose of study treatment&#xD;
&#xD;
               -  Current dyspnea at rest because of complications of advanced malignancy or any&#xD;
                  medical need for continuous oxygen therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center; Medical Oncology</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>November 21, 2018</last_update_submitted>
  <last_update_submitted_qc>November 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Maytansine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

